MPLT Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

37.265

Open

35.050

VWAP

36.21

Vol

588.35K

Mkt Cap

1.68B

Low

34.310

Amount

21.30M

EV/EBITDA(TTM)

Total Shares

45.35M

1.28B

EV/OCF(TTM)

P/S(TTM)

MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of patients suffering from debilitating central nervous system disorders (CNS). Its lead product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist, ML-007, co-formulated with a peripherally acting anticholinergic (PAC), which it is initially developing for the treatment of schizophrenia and Alzheimer’s disease psychosis (ADP). ML-007C-MA is designed to activate both M1 and M4 muscarinic receptors in the CNS to drive efficacy, while synchronizing the pharmacokinetics of the agonist and antagonist components to mitigate peripheral cholinergic side effects. Its second product candidate, ML-004, is a 5-HT1B/1D agonist that the Company is developing for the treatment of social communication deficit and/or irritability in autism spectrum disorder. It is also advancing two preclinical programs, ML-021 and ML-009.

Events Timeline

(ET)

2026-06-22

07:30:00

MapLight Therapeutics Announces ML-004 Autism Study Results

2026-05-21 (ET)

2026-05-21

16:30:00

Nasdaq Rises on Nvidia Earnings Report

2026-05-21

12:00:00

Nasdaq Declines as Nvidia Announces $80B Buyback

News

8.5

06-26NASDAQ.COM

Biotech Sector Update: FDA and EU Approvals

6.0

06-25seekingalpha

Raymond James Initiates Strong Buy Ratings for Tonix and MapLight

5.0

06-24Newsfilter

MapLight Therapeutics Appoints New Board Members

9.0

06-22NASDAQ.COM

MapLight's Autism Drug Trial Fails to Meet Primary Endpoint

6.5

05-30Yahoo Finance

FCPM III Reduces Stake in Dyne Therapeutics by $14 Million

6.0

05-27CNBC

Wall Street's Latest Rating Changes Overview

4 Analyst Rating

Wall Street analysts forecast MPLT stock price to rise

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

28.00

Averages

31.00

High

34.00

Current: 0.000

Low

28.00

Averages

31.00

High

34.00

Raymond James

Strong Buy

initiated

$46

AI Analysis

2026-06-24

Reason

Raymond James

Price Target

$46

AI Analysis

2026-06-24

initiated

Strong Buy

Reason

Raymond James initiated coverage of MapLight Therapeutics with a Strong Buy rating and $46 price target. Cobenfy marks the first major mechanistic innovation in schizophrenia treatment in over three decades, but it "suffers from a persistence problem," says the analyst, who believes the risk/reward into ML-007C-MA's Phase 2 ZEPHYR readout by mid-August is "skewed to the upside." While adding that the "Street has a tendency to dismiss anything Alzheimer's-related," the analyst argues that MapLight's Alzheimer's disease psychosis program is "under-the-radar" and "could emerge as a real value driver."

Craig-Hallum

Buy

downgrade

$43 -> $40

2026-06-23

Reason

Craig-Hallum

Price Target

$43 -> $40

2026-06-23

downgrade

Buy

Reason

Craig-Hallum lowered the firm's price target on MapLight Therapeutics to $40 from $43 and keeps a Buy rating on the shares. MapLight's ML-004 Phase 2 IRIS results were mixed but not thesis-breaking, with the firm noting a missed primary endpoint in social communication but a meaningful benefit in a defined adolescent subgroup for irritability with better tolerability than existing antipsychotics, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MPLT

Unlock Now

Valuation Metrics

The current forward P/E ratio for MapLight Therapeutics Inc (MPLT.O) is 0.00, compared to its 5-year average forward P/E of -4.45. For a more detailed relative valuation and DCF analysis to assess MapLight Therapeutics Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.45

Current PE

0.00

Overvalued PE

-3.79

Undervalued PE

-5.11

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-5.14

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

-4.52

Undervalued EV/EBITDA

-5.76

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

AI Analysis

Annual

Quarterly

Whales Holding MPLT

Trading Trends

People Also Watch

Frequently Asked Questions

What is MapLight Therapeutics Inc (MPLT) stock price today?

The current price of MPLT is 37.06 USD — it has increased 5.76

What is MapLight Therapeutics Inc (MPLT)'s business?

What is the price predicton of MPLT Stock?

Wall Street analysts forecast MPLT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MPLT is31.00 USD with a low forecast of 28.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.